Scotiabank raised the firm’s price target on Beam Therapeutics (BEAM) to $25 from $24 and keeps a Sector Perform rating on the shares. The firm likes the company’s setup for the rest of the year, but remains cautious until more clinical derisking occurs, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Cautious Optimism for Beam Therapeutics Amid Upcoming Milestones and Financial Considerations
- Beam Therapeutics: Promising Pipeline and Strong Financial Position Justify Buy Rating
- Biotech Alert: Searches spiking for these stocks today
- Beam Therapeutics: Anticipated Growth Driven by BEAM-302 and SCD Franchise Progress
- Beam Therapeutics Reports 2024 Financial Results and Progress